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Hamilton II, Mark. M.S.B.M.E., Purdue University, August, 2014. Standardizing 
the Collection and Measurement of Glucose in Exhaled Breath and its Relationship to 
Blood Glucose Levels.  Major Professor:  Ann E. Rundell. 
Blood glucose level control (glycemic control) is crucial in diabetes. Limitations 
in current commercially available monitoring devices include causing patient pain 
leading to poor blood glucose level management. The development of a non-invasive 
measurement system may lead to improved patient glycemic control, reducing unwanted 
side-effects and complications of poor blood glucose level maintenance. 
This work explores the use of glucose within exhaled breath in attempt to 
establish an indirect method of blood glucose level measurement. Specifically, exhaled 
breath condensate (EBC) is examined. A breath condensing unit was designed to measure 
the temperature of the system, flow rate, volume of expired air, ambient humidity, and 
remove exhaled dead volume before condensing breath. A fluorometric assay was used to 
analyze and measure the glucose concentrations in the EBC samples. The results directly 
relate to the feasibility of developing a noninvasive EBC-based glucose measuring 
device. 
A nebulizer study was performed to verify that the amount of glucose present in 
the condensate was predictable, given a known concentration of aerosolized glucose. The 
nebulizer study revealed that some glucose interferent is present in the ambient air. 
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Further exploration allowed for a humidity based model to be developed that can 
accurately and consistently predict the concentration of the condensate. 
 An IRB approved study, using a total of five human subjects, was 
employed to quantitatively evaluate the change in both blood and EBC glucose levels 
associated with the intake of either food or water. The human subject study results 
indicate that, with the use of the humidity based model derived from the nebulizer study, 
it is possible to predict blood glucose levels from EBC glucose levels. These results 








Diabetes Mellitus, often referred to simply as diabetes, is a disease in which 
affected individuals are unable to autonomously control their blood glucose levels due to 
either a lack of insulin receptors or insufficient levels of insulin production [1]. Instead, 
diabetic patients require the aid of blood glucose monitoring systems and exogenous 
insulin to maintain normal physiological glucose levels. If blood glucose levels are left 
unchecked and allowed to remain too frequently outside healthy levels, the patient may 
become victim to more serious medical conditions including: lower-limb numbness, 
stroke, blisters, glaucoma, hypertension, neuropathy, and diabetic coma [2]. Diabetes is 
diagnosed as one of three categories, Type 1, Type 2, and Gestational Diabetes, which 
combined are estimated to affect 8.3% of the U.S. population or 25.8 million people [3].  
Type 1 diabetes, previously known as juvenile diabetes, affects approximately 5% 
of the total diabetic population [4]. Patients with Type 1 diabetes cannot produce insulin 
because their bodies have attacked and destroyed their insulin producing pancreatic beta 
cells [4]. As such, the only form of treatment currently available to Type 1 diabetics is 
active blood glucose level monitoring coordinated with self-administered doses of insulin 
delivered via injection or pump. 
Type 2 diabetes, commonly known as adult onset diabetes,  is the most common 
form of the diabetes accounting from 90% to 95% of all diagnosed cases of diabetes [3]. 
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This form of diabetes normally begins with the body’s inability to properly use its 
insulin, or insulin resistance [5]. Initially the pancreas produces additional insulin to 
compensate, however, as the need for insulin continues to rise the pancreas gradually 
begins to lose its ability to make more [3]. The early stages of Type 2 diabetes can be 
controlled with a healthy meal plan and exercise, but as the disease progresses it will 
require Type 1 level treatment to maintain healthy blood glucose levels. 
Gestational diabetes is a temporary form of glucose intolerance that may develop 
during pregnancy. It is often diagnosed around the 24
th
 week of and does not indicate 
diabetes outside the pregnancy [6]. However, 5% to 10% of women diagnosed with 
gestational diabetes are diagnosed with Type 2 diabetes immediately after birth and 35% 
to 60% are diagnosed with Type 2 diabetes within 20 years [3]. 
Most complications of diabetes manifest themselves when blood glucose levels 
are allowed to shift drastically, or attain and sustain dangerous levels; thusly, strict blood 
glucose level control (glycemic control) can prevent or delay complications [7]. This 
typically involves keeping blood glucose levels between 70 and 130 mg/dL before meals 
and less than 180 mg/dL two hours after a meal. To put these values into perspective, the 
fasting levels of blood glucose used to diagnose diabetes are enumerated in Table 1.1 [8]. 
In addition to mitigating health complications from diabetes, strict glycemic control also 
reduces the financial burden of the disease long term [9-11]. However, patients struggle 
to maintain these preventative measures [12-14] citing the following as reasons to 
monitor blood glucose less frequently than recommended: testing my blood sugar as 
often as recommended would be expensive, painful, and unpleasant [15]. Patient 
discomfort and unease provides motivation to develop a painless and cheap blood 
monitoring system in hopes to promote better glycemic control. 
Table 1.1: Fasting blood glucose levels and their corresponding diagnostic significance. 
No food or drink, with the exception of water, should be consumed eight hours prior to 
the test. 
Diagnostic Significance Fasting Plasma Glucose 
Normal < 100 mg/dL 
Prediabetes 100-125 mg/dL 
Diabetes ≥126 mg/dL 
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1.2 Minimally Invasive and Commercially Available Methods of Blood Glucose 
Monitoring 
1.2.1 Single reading self-monitoring blood glucose devices 
The most widely accepted and universally used self-monitoring blood glucose 
(SMBG) device is the glucose meter and it is the standard of SMBG for the American 
Diabetes Association (ADA) [16]. The glucose meter has undergone much improvement 
since its release in 1970 including miniaturization, disposable sensors, smaller sampling 
volume, and shorter measuring time [17, 18]. Despite how far these devices have come, 
device accuracy remains an issue [19] and there is a large disconnect between 
commercial product and academic research [20]. Glucose meters typically operate via 
blood sampling. Patients sample capillary blood by using a lancet to prick their fingers 
and then apply a drop of blood to the sensor of the device [16]. The two primary methods 
of glucose quantification in most SMBG devices use electrochemistry or photometry to 
measure the oxidation of glucose through either glucose dehydrogenase or glucose 
oxidase [21]. Typical patients may have to measure their blood glucose levels three or 
more times a day, though blood glucose sample frequency will vary between individuals 
[22]. 
1.2.2 Continuous blood glucose monitoring 
Continuous glucose monitoring (CGM), where a device monitors fluctuations of 
blood glucose in near real time, may be an achievable method of alleviating high glucose 
measurement frequency of some patients. Unfortunately, CGM systems are unavoidably 
at least minimally invasive. They range from implantable devices, which are fully 
invasive, to trans-dermal, which can be minimally invasive [19]. Additionally, CGM 
devices cannot entirely rid the patient of SMBG finger pricks as most of these devices 
will intermittently require calibration with a SMBG device, such as a glucose meter[23]. 
There are a number of CGM devices commercially available, and there is significant 
research in the field of a closed loop CGM device [23]. A closed loop CGM device 
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involves combining the device with an insulin pump and a controller, allowing the device 
to dose insulin as needed if the blood glucose level becomes elevated. The system would 
effectively allow the patient strict glycemic control with little device interaction.  Current 
limitations of CGM devices include accuracy, durability, reliability, and lag time [23]. 
The perfection of such a device would in essence be the creation of an artificial pancreas, 
and this is the focus of much diabetic research [24]. Much progress has been made on the 
path to an artificial pancreas on the CGM, insulin pump, and controller fronts, but it is 
still far from being commercially available [25]. However, when it does become 
commercially available, the closed loop system has the possibility to take out patient 
error and negligence out of glycemic control. 
 
1.2.3 Limitations of commercially available glucose monitoring devices 
A majority of the diabetic patient population utilizes SMBG systems to aid their 
glycemic control [19, 21], it thereby seems prudent to focus on SMBG future directions 
and limitations. Each diabetic patient is recommended to test their blood glucose levels 
according to the severity of their diabetes, however, more frequent measurements allow 
for a more complete understanding of the patient’s glucose metabolism and better 
glycemic control [16]. Accompanying each additional measurement is another prick of 
the finger, another test strip and lancet used, and another period of time patients need to 
allot out of their day. It is a direct tradeoff between better glycemic control and more 
discomfort (physically, mentally, and financially) to the patient [15]. A non-invasive 
method of blood glucose monitoring would mitigate the negative aspects of frequent 




1.3 Non-Invasive Measurement of Blood Glucose Levels 
1.3.1 Imaging 
Many different imaging modalities are currently being explored in attempts to 
non-invasively measure blood glucose levels, including: near-infrared (NIR) 
spectroscopy, mid-infrared (MIR) spectroscopy, ultrasound, photoacoustic spectroscopy, 
and Raman scattering [26, 27]. Within non-invasive diabetic research NIR spectroscopy 
has accrued amongst the most depth and breadth of research [28-30], but most of these 
methods share similar limitations [31]. Glucose does not produce a strong consistent 
signal in most of these modalities and there is considerable interference from undesired 
tissues and substances, therefore precision and consistency are inherently two challenges 
to non-invasive blood glucose level imaging [30-35]. There are some imaging sensors 
already produced by companies, but unless these problems can be overcome they are 
currently not of use to the diabetic patient population [31]. 
1.3.2 Indirect measurement through biological liquids 
Significant amount of non-invasive blood glucose monitoring research has been 
focused on using other, more readily available, patient liquids. Urine, saliva, and tears 
have all been analyzed in attempts to find a relationship between their constituents and 
blood glucose levels [17, 36-45]. Urine analysis was part of the foundation of diabetes 
diagnosis, as glucose is excreted in urine when blood glucose concentration gets too high 
[17]. Unfortunately this primarily happens upon atypically high glucose concentrations 
for healthy individuals, rendering urine ineffective as an indirect blood glucose 
measurement. Saliva analysis superficially would appear to be very relevant in 
monitoring glucose metabolism; however, saliva glucose concentrations are more closely 
related to the sugar content and timing of the previous meal [46]. This allows saliva 
analysis to aid in short term glycemic control but limits its all-day monitoring uses [39, 
42, 43]. Functional relationships between tear glucose levels and blood glucose levels 
have been thoroughly investigated [36-38, 44, 45]. This work is leading toward a 
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wearable sensor that would be placed over the eye, akin to a contact lens [40, 41]. Some 
limitations of a contact lens form of indirect blood glucose monitoring are patient appeal, 
discomfort, and cost. 
1.3.3 Indirect measurement through exhaled breath and exhaled breath 
condensate (EBC) 
The body of this thesis focuses on the use of exhaled breath condensate (EBC) for 
use as an indirect measurement of blood glucose level due in part to its non-invasive 
nature and minimal perceived inconvenience to the patient. EBC sampling and analysis 
has been performed since the 1980s [47] and it has since expanded into a thriving and 
promising non-invasive testing method [48-50].  Breath acetone, for example, has been 
used to in diabetes diagnostics and has been investigated as a biomarker for glucose 
metabolism [51, 52]. Specifically, this work investigates glucose in EBC. Glucose has 
been detected in EBC samples but is not yet well characterized [46]. The physiology and 
theory behind EBC collection and analysis will be elaborated on later in the thesis. 
 
 
1.4 Significance of a Non-Invasive Glucose Measuring Device 
The main purpose of developing a non-invasive glucose measuring device is to 
make strict glycemic control more achievable for all diabetic patients. Assisting patients 
to properly dose their insulin or otherwise maintain their blood glucose levels will 
significantly lower the medical complication rate associated with diabetes and reduce the 
overall healthcare costs rooted in diabetes. The top three reasons cited from a patient 
survey monitor blood glucose less frequently than recommended: testing my blood sugar 
as often as recommended would be expensive, painful, and unpleasant [15]. EBC analysis 






1.5 Immediate Goals 
The American Thoracic Society (ATS) and the European Respiratory Society 
(ERS) created a joint task force in 2005 to address the state of EBC research. A major 
finding of the task force was a lack of consistency in measurement techniques for each 
biomarker [48].  As glucose is not yet well categorized in EBC samples, following the 
recommendation of the ATS/ERS task force seems prudent. Provided that the ideal final 
product of this research would result in an affordable, handheld glucose breathalyzer that 
can accurately monitor blood glucose levels, the immediate goals of this work are listed 
below: 
 Standardize a method of collecting and measuring glucose concentrations 
from aerosol 
 Design a device to collect exhaled breath condensate 
 Evaluate the relationship between exhaled breath condensate glucose 







2.1 Lung Physiology and EBC 
Exhaled breath contains water vapor and various solutes originating from 
epithelial lining fluid (ELF) that can be collected and analyzed as liquid EBC [53]. EBC 
consists mostly of condensed water vapor, with the other molecules representing a very 
small fraction (~0.01%) [54]. ELF is diluted up to 10,000 times in EBC by water vapor, 
making measurement of ELF components in breath challenging due to low signal to noise 
ratios [46]. It is presumed that the contents of the ELF come to equilibrium with the 
blood in the surrounding capillary, thusly the content of EBC have been heavily 
investigated [50, 54-58]. It still remains uncertain how endogenous non-volatile 
molecules, such as glucose, are aerosolized during respiration. Two hypotheses prevail: 
(1) turbulent flow in the lungs may force droplets of ELF into the air [58]; (2) ELF 
droplets may be released into the breath when a film of ELF, formed during the prior 





2.2 EBC and Diabetes 
A majority of breath related diabetes work has focused on volatile endogenous 
biomarkers, some of which are byproducts of the disease itself [60-63]. Some examples 
of volatile diabetes related biomarkers include, but are not limited to, acetone, carbon 
dioxide, ethanol, and methyl nitrate [60]. Acetone had been an unquantified indicator of 
diabetes long before its use in breath research as physicians would recognize its fruity 
smell; it was later discovered to be the result of diabetic ketoacidosis and related to 
insulin resistance [52, 64]. While acetone has been detected and measured in breath, it is 
yet to be correlated with blood glucose levels and varies between diabetic and non-
diabetic patients [65]. Carbon dioxide is a known product of both glycolysis and the 
Krebs cycle, both of which involve the breakdown of simple sugars. Based on this 
knowledge, a patent has been filed to utilize glucose labeled with high molecular weight 
carbon (13C) to indicate metabolism [66]. The 13C test works well as a diagnostic tool, 
to assess glucose metabolism over a certain period of time but is limited as not all sugar 
consumed by the patient can be 13C labeled [67, 68].  Breath ethanol has shown promise 
in its relation to blood glucose levels and it is typically used in conjunction with acetone 
as a biomarker [60, 69]. Methyl nitrate, produced primarily by hyperglycemic oxidative 
stress, has been used to track some diabetic blood glucose levels but does not translate for 
all patients [60, 70, 71].  
Regardless of the biomarker measured, it must be noted and accounted for that the 
measurement is not a direct measurement of the ELF. Any volatile biomarker condensed 
for sampling will be heavily diluted, approximately 2,500 times, by the simultaneously 
condensed water vapor [53, 54]. This estimate was obtained using sodium and chlorine 
ion measurements in EBC and ELF to determine dilution. The possibility of glucose 
measurements being similarly diluted should be considered. However, glucose cannot be 
directly compared to the prior potential breath biomarker examples because glucose is not 
volatile nor is it a by-product of diabetes. 
There has been a push for both sensitivity and real time measurement within 
breath research with such technologies as selected ion flow tube mass spectrometry 
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(SIFT-MS) and cavity ring-down spectrometry [65, 72-78]. These approaches have been 
shown effective for volatile molecules, but they are currently lab bench technologies 
unsuitable for individual patient use. Additionally, most of these technologies focus on 
volatile biomarkers with little interest in the non-volatile components of the breath. Gas 
chromatography and anion-exchange chromatography are also frequent measurement 
techniques for breath research, unfortunately these often require lyophilization to be most 
effective [54, 79]. 
 
2.3 Commercially Available and Patented EBC Collection Devices 
A majority of the commercial EBC collection devices pass breath through a cold 
condensation chamber where the breath is condensed [80-84]. The samples are then 
typically stored in sterile containers until they can be analyzed. The marketed devices are 
effective for measuring a set list of biomarkers, but have little direction for analysis of 
biomarkers not present on their lists [85, 86]. Additionally, these collection devices are 
very expensive [87]. 
2.3.1 ECoScreen 
ECoScreen is a multiple use, non-invasive EBC collection system. The 
ECoScreen cools the passing breath to -10°C to condense the water vapor and aerosolized 
particulate and suggests a collection time of 5-15 minutes. Its suggested uses are for: 
detection of lower airway inflammation, assessment of bronchial challenge testing, and 
identification of tumor markers [85]. All analysis must be done by the researcher with 
little suggestion on how to test for biomarkers (Jaeger Teonnies, Hoechberg Germany, 
(http://spira.fi/data/attachments/020_ECoScreen_Brochure.pdf). 
2.3.2 RTube 
RTube is a single use, non-invasive EBC collection system. Using an RTube, the 
patient breaths into a vertical tube encased in a cooling sleeve [86]. The breath is 
11 
 
condensed in the vertical tube, then to be removed via plunger and stored in the RTube 
disposable tube. There is no set collection time and again little aid is offered in the means 
of analysis (Respiratory Research Inc., Charlottesville Va, 
http://respiratoryresearch.com/products-rtube-overview.htm). 
2.3.3 EBC related patents 
Many patents detailing many aspects of EBC collection and many potential 
biomarkers have been filed, even some that suggest the collection and measurement of 
glucose [88-92]. While these patents are promising for the progress of EBC related 
diabetic research, as of the writing of this thesis there has been no research released 
correlating the glucose measurement of EBC to that of the blood. In order for any glucose 
based EBC device to succeed, a function relationship between the breath and blood 
glucose levels must be established. 
 
2.4 Glucose Detection and Measurement in EBC 
Table 2.1, based on a table from a prior thesis on this work [93], displays non-
lyophilizing methods of glucose measurement in liquid samples. Given a desired lower 
limit of 0.1 mg/L, it was found that BioVision’s glucose assay kit (BioVision catalog 
number: K606-100, http://www.biovision.com) had sufficient sensitivity while being 
simple and relatively inexpensive. It should be noted that blood glucose measurements 




Table 2.1: Glucose measurement methods, associated detection limits, and references. 
Based on a table from a thesis by Arun Mohan [93]. 
Method Detection Limit Reference 










Amperometric glucose biosensor based on carbon nanotubes and 




Glucose oxidase in poly(o-aminophenol) film on polypyrrole-Pt 




Biosensor based on poly(methylene blue) and Au colloid modified 









MnO2-GOx carbon paste electrode  0.55 mg/L 
Wang (2008) 
[99] 
Biosensor based on immobilization of glucose oxidase in 
electrochemically polymerized polytyramine film and overoxidised 






2.5 Prior Studies 
In a prior study, by Arun Mohan under the direction of Ann Rundell, using a total 
of 13 human subjects, EBC and blood glucose levels were measured over the course of 
three hours with a provided meal [93]. Five subjects returned to participate in the same 
procedure two more times on different days. 
2.5.1 Collection device 
The experimental setup for the prior study is shown in Figure 2.5.1. The system 
was comprised of two chambers, the preliminary chamber and the condensation chamber. 
In order to prevent early condensates from forming, the preliminary chamber was kept at 
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37°C. It housed the capnometer (CO2 analyzer), solenoid valve, and primary reservoir. As 
the subject exhaled, initially the airflow was directed out of the system. To remove air 
from dead space within the lungs and collect only air from the gas exchange region of the 
lungs, the capnometer triggered the solenoid and moved the air flow through the system 
when it read CO2 values associated with end tidal air. That air was then collected in the 
primary 5L reservoir. Once the primary reservoir filled, the subject was finished with the 
breath sample.  
Starting by emptying the filled primary reservoir, the collected breath was passed 
through the condensation chamber via a stainless steel tube, filling a secondary reservoir. 
The collected breath was passed back and forth between the two bags until enough EBC 
volume was produced. The air passing between the two bags was regulated with a flow 
regulator and that flow rate was monitored by a pneumotachometer.  
2.5.2 Glucose assay kit and analysis 
In order to detect and quantify glucose in the collected EBC samples, a BioVision 
glucose assay kit was used (#K606-100, http://www.biovision.com). The kit utilizes 
glucose oxidase to transform glucose into gluconic acid and hydrogen peroxide. 
Hydrogen peroxide then attaches to the kit probe. The mechanism is shown in Figure 
2.5.2. The reaction is covered and kept at 37°C for 30 minutes. When the mixture is hit 





Figure 2.5.1: Experimental setup for Mohan thesis [93]. There are two main 
compartments, the preliminary chamber and the condensation chamber. The preliminary 
chamber is kept at 37°C to avoid premature condensation, while the condensation 
chamber is filled with dry ice. 
 
 
Figure 2.5.2: BioVision glucose assay kit mechanism [93] 
 
The assay results were analyzed using a fluorescent spectrometer yielding relative 
fluorescence units (RFUs). The RFU are converted to glucose concentration units by the 
generation of a standard curve from known glucose concentrations. 
2.5.3 Human subject EBC and blood collection procedure 
All subjects were asked to fast three hours prior to participating in the study. 
Three breath samples were collected prior to the provided meal at approximately ten 













breath samples were taken every ten minutes for two hours. With every breath sample, 
both before and after the meal, a blood glucose measurement was taken. In order to 
measure blood glucose levels, a drop of blood was obtained by pricking the subject 
fingertip with a lancet. The drop of blood was then analyzed for glucose concentration by 
an ACCU-CHEK Nano glucometer (Roche Diagnostics). Breath samples were collected 
using the device depicted in Figure 2.5.2 and analyzed using the BioVision glucose assay 
kit. 
2.5.4 Results 
One subjects test can be seen in Figure 2.5.3 with blood glucose levels denoted in 
red and EBC glucose levels in blue. Both blood and EBC show an increase in glucose 
level after the subject was provided a meal.  
 
 
Figure 2.5.3: EBC (blue) and blood (red) glucose trend over 2.5 hours of sample 




The two major findings of this study were the dilution factor from blood glucose 
levels to EBC glucose levels and the effects of a meal on EBC glucose levels. The 
dilution factor was found to be ~1800, but very variable with a standard deviation of a 
~1400. The EBC samples taken prior to the meal were significantly different than both 
the three samples taken directly after the meal and the last three samples taken from the 
patient. 
2.5.5 Summary and conclusions 
This study suggests the feasibility of an EBC based glucose monitoring device. 
EBC significantly changing after a meal provides a basis for future work in this area. 
However, the variability of the blood-to-breath glucose ratio suggests that more has to be 
done to understand the blood and EBC relationship. Following theses promising results, 





3 PORCINE SUBJECT STUDY 
From the prior study, it became clear that is a lot yet to be understood about the 
blood-to-breath relationship. Given that the blood glucose levels within a human subject 
vary according to the patient’s homeostatic control, it becomes difficult to assess the 
variability of EBC glucose due to its expected dependence on blood glucose levels. To 
thoroughly examine EBC variability and factors that may contribute to EBC variability, it 
would be beneficial to hold the subject blood glucose level steady. Using an animal 
model, porcine in this case, it is possible to control the subject blood glucose levels and 
use constant blood glucose levels to better understand its relationship to EBC glucose 
levels. 
 
3.1 Breath Collection Setup 
The collection setup used in the porcine study is very similar to the one described 
in the thesis by Arun Mohan (Figure 2.5.1) but there are a few key differences. For ease 
of collection the pigs used in this study were anesthetized, meaning that the anesthetic 
delivery circuit must be incorporated into the breath collection setup. During collection, 
the subject has a tracheal tube inserted allowing delivery of anesthetic gases in 100% O2 
while directing the exhalation toward the collection device.  The collection and 




Figure 3.1.1: Porcine experiment setup for collecting and condensing breath. 
 
The top portion of Figure 3.1.1details the collection setup. Upon exhalation, the 
breath first passes through a capnometer followed immediately by a pneumotachometer 
to measure the partial pressure of CO2 and air flow rate respectively. As the gas exchange 
responsible for the presence of glucose in the breath is suggested to occur at the alveolar 
level, the dead space that has no alveolar interaction does not contribute to the EBC 
glucose. Dead space air similarly does not acquire CO2 from the gas exchange. By 
triggering the solenoid valve based on the capnometer output, the solenoid valve forces 
air with little CO2 (dead space) to be dispelled out of the system while collecting the air 
with more CO2. The dead space relationship to CO2 content is detailed in Figure 3.1.2 
(adapted from the Mohan thesis [93]) and the solenoid switching mechanism is 
represented in the top right corner of Figure 3.1.1. From the solenoid valve the air to be 




Figure 3.1.2: Illustration of dead space dependence on CO2 content. The red dashed line 
represents a potential trigger level for the solenoid switch [93]. 
 
Once the collection reservoir is filled, its end is clamped shut until it can be 
attached the condensation setup (bottom of Figure 3.1.1). The collected breath is passed 
between reservoirs until each reservoir has been emptied ten times. Each time the breath 
travels from one reservoir to the other, it passes through a stainless steel tube surrounded 
by dry ice. After each reservoir has been emptied ten times in this setup, the reservoirs 
are removed and the sample is collected in a microcentrifuge tube via plunger. 
 
3.2 Research Design 
The Purdue Animal Care and Use Committee (PACUC) approved protocol 
1203000611 included up to 30 porcine subjects for the following three aims: 
1) Establish a quantitative relationship between the glucose levels in the EBC 
and blood using porcine subjects 
 





























































2) Validation of the quantitative relationship from Aim 1 to accurately predict 
the blood glucose levels in the porcine subject 
3) Optimize EBC instrumentation and collection parameters. 
Up to ten pigs were allotted for each aim and each subject was to be anesthetized and 
ultimately sacrificed. Every subject had ECG and blood pressure monitoring in addition 
to a femoral vein catheter for the administration of fluids. The blood glucose levels were 
to be adjusted with intravenous (IV) administration of dextrose or insulin and sustained 
with somatostatin [101, 102]. Exhalation mode, respiration rate and inhale-exhale duty 
cycle were all to be altered to control the breathing style using phrenic nerve stimulation 
and abdominal compression [103].  
None of the aims were completed and Aim 1 was the only one attempted. A total 
of seven subjects were run. 
 
 
3.3 Establish a Quantitative Relationship between the Glucose Levels in the EBC 
and Blood Using a Porcine Subject 
3.3.1 Methods 
The experimental factors and the target levels at which they were evaluated were 
listed in Table 3.1Table 1.1. The experiment design randomly ordered the three target 
blood glucose levels with six random combinations of ventilation related factors at each 
glucose level. Before any EBC sample was taken, the blood glucose had to be stable 
within 10% of the desired level for 10 minutes (as confirmed by 3 blood glucose samples 
collected at least 2-3 minute apart) and ventilation factors had to be stabilized for at least 
5 minutes prior to EBC sample collection. Blood glucose levels were controlled with an 
IV dextrose or insulin. It took about 10 minutes to collect each breath sample using the 
setup described in 3.1 Breath Collection Setup. Prior to the experiment, the veterinary 
technician attached a cuff-electrode to the subject’s phrenic nerve and an automated 
compression machine (thumper) was attached to its abdomen. The cuff electrode was 
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controlled by a grass amplifier. Together, the cuff electrode and thumper were used to 
control the subject’s breathing patterns to match those listed in Table 3.1. Allowing for 
adjustments to the glucose levels and the stabilization of the ventilation factors, each 
study lasted between 6 to 8 hours for the anesthetized subject.  At the conclusion of the 
day, the subject was euthanized.  
Data analysis and model generation employed repeated measures ANOVA to 
analyze the EBC and blood glucose concentration, respiratory rate, peak inspiratory and 
expiratory air flow rates, tidal volume, exhale duration, and minute ventilation.  
Table 3.1: Experimental Factors 
Factors Level 1 Level 2 Level 3 











Resting Rate Held breath (inspiration 
3 times longer than 
exhalation) 
Shallow breath 
(inspiration 3 times 
shorter than exhalation) 
Respiration rate Resting Rate Rapid (~40 breaths/min) N/A 
 
3.3.2 Results 
With each subject, the blood glucose level was successfully controlled and 
maintained with dextrose, insulin, and somatostatin at all the desired levels of Table 3.1. 
However, as the chest compressions and phrenic nerve stimulation were applied they 
began to affect the health of the subject. While the breath rate and force were being 
controlled, the subject would become unstable before any pattern could be established for 
that subject. As such, it was decided to focus on the achievable different blood glucose 
levels. Regrettably, randomized glucose levels were unachievable as each blood glucose 
level change substantially increased collection time and frequent swings in blood glucose 
level also affected subject viability. The attempt at Aim 1 of the PACUC approved study 
was reduced to breath correlations of three constant blood glucose levels. 
Figure 3.3.1 provides an example of the blood and EBC glucose levels collected 
from a porcine subject from Aim 1. The blood glucose levels were maintained at the 
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normal (~100 mg/dL) and elevated (~200 mg/dL) with repeatable consistency. The breath 
glucose levels seem to be relatively similar with the exception of two markedly higher 
readings. The two samples that read higher than the rest coincide with raised blood 
glucose values. Overall, there was no significant different between EBC samples from 
elevated, normal, or hypoglycemic pig blood glucose levels (p=0.382; n=7). Refer to 
Appendix A 
Whole Pig Study Data for data from the other six subjects.
 




The porcine studies did not yield the results expected. Constant elevated, normal, 
and hypoglycemic pig blood glucose levels did not have a significant effect on the EBC 
samples (p=0.382; n=7). Samples collected while the patient maintained normal blood 
glucose levels appear approximately as expected; they are low in the assay limits with an 






































































corresponding to elevated blood glucose levels are less logical. The average value and 
standard deviation for such samples are 1.47±1.85 mg/L. In this case, the variance 
inherent in these measurements is greater than the average value. Looking at Figure 3.3.1, 
it is clear that primarily two sample are responsible for this variability. The relationship 
of the EBC sampled during normal glucose levels to the EBC values during elevated 
glucose levels is also perplexing, as the two highly concentrated values from the elevated 
glucose levels are more intuitive than the majority.  
Provided the lack of understanding and progress achieved by the seven subjects in 
this study, it was decided that further in-vitro investigation of the collection and 





4 COLLECTION AND MEASUREMENT OF GLUCOSE IN 
AEROSOL 
The difficulty faced in the porcine study suggested that it is impractical to analyze 
biological variance when the collection mechanisms are not fully understood. Therefore, 
a method of assessing the collection and measurement protocols not involving biological 
subjects needed to be developed. One way to accomplish this would be through the use of 
simulated breath with known and controlled glucose levels. The following study used a 
nebulizer to simulate breath of known concentrations and investigate the process of 
collection and measurement of glucose in the resulting mixture. It should be noted that 
the data and some description of this following chapter was submitted in a different 




4.1 Initial Nebulizer Glucose Standard 
In addition to removing the biological variable from the process to isolate the 
collection procedure itself, it seemed prudent to simplify the system further and focus 
primarily on the collection and measurement. Therefore, the extraneous elements of the 
pig collection setup were removed for the nebulizer study. Additionally, a majority of 
EBC research does not utilize any bag collection reservoir for smaller total volume [48]. 
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Instead, the subject breathes through the device which ends with the condensation tube 
and the breath vacating into the room.  
4.1.1 Nebulizer collection setup 
The setup for the nebulizer experiment is depicted in Figure 4.1.1. The nebulizer 
used in this study is ultrasonic, meaning it pushes the liquid through a very fine vibrating 
mesh resulting in small (respirable) aerosolized droplets (Omron MicroAir, Omron, 
Kyoto, Japan). The dead space accrued by the connective tubing was 13 ml. Dry ice in 
the container surrounding the condensation tube lowered the temperature inside causing 
condensate to form and eventually freeze on the interior of the condensation tube. The 
condensation tubes were then warmed to room temperature in 3-5 minutes and the 
samples were poured into sterile microcentrifuge tubes and frozen at -80 °C until assayed. 
Samples were thawed and assayed in a batch within three days of collection. Samples 
were generated by nebulizing five milliliters of solution into the collection device (Figure 
4.1.1).  Collection was performed for five minutes as the output was drawn through the 
condensation tube using a vacuum (Schuco Vac, Carle Place, NY) at a flow rate of six 
liters per minute. 
 
 
Figure 4.1.1: Aerosol condensation and collection device.  The condensation tube runs 
through a container filled with dry ice, causing the breath and aerosol passing through the 
tube to condense. A section of the condensation tube is shown at a higher magnification 
to illustrate the condensation process. The vacuum draws the output of the nebulizer 




4.1.2 Nebulizer collection methods 
The concentrations to be used in the nebulizer were based on the BioVision 
glucose assay kit. The kit uses concentrations of 0, 0.72, 1.44, 2.16, 2.88, 3.6 mg/L to 
create its standard. Five milliliters of each listed concentration were added to the 
medicine cup of the nebulizer. The initial solution added to the nebulizer is referred to as 
‘stock’ or ‘nebulizer input’ throughout this study. Once a collection was finished, liquid 
that was not aerosolized remains in the medicine cup of the nebulizer. That leftover liquid 
was referred to as ‘remnant’ in this study. Finally, the sample that condensed in the 
condensation tube from the nebulizer output is referred to as ‘condensate’ throughout this 
study. For this and all following studies, the condensation tube and connective tubing 
(Tygon® R-3606) were cleaned with ethanol and dried with dry, cleaned air (oil-free, 0.2 
µm filtered pressurized air with a dew point of -40 °C) before initial use and between 
each sample collection. A generalized linear model was run to analyze the data with 
Tukey tests run for pairwise comparison.  
4.1.3 Results 
The expected study results of running the nebulizer standard were that all samples 
(stock, remnant, and condensate) have the same glucose concentrations. However, as 
indicated by Figure 4.1.2, all three samples do not produce the same glucose 
concentrations. The stock and the remnants samples were significantly different from the 
condensate collected (p < 0.001). Aerosolization of glucose solutions with concentrations 
of 1.44 mg/L and greater yielded condensate concentration lower than the stock, while 
solutions of 0.72 mg/L produce similar condensate concentration to the input and no 





Figure 4.1.2: The glucose concentrations from condensate (n=9), remnants (n=9), and 
stock (n=9) samples from a nebulized glucose standard. Groups that do not share a letter 
are significantly different. 
 
4.1.4 Discussion 
The stock and the remnants had the same glucose concentrations for all stock 
values. However, the condensate differed in glucose concentration inconsistently 
throughout the range of stock concentrations. From this it is clear that the nebulizer itself 
has no effect on glucose concentration, as the stock and remnants have the same glucose 
concentration. However, there must be something unaddressed that is contributing to the 
condensate glucose concentration. This provides some explanation for why it was 
difficult to find a relationship between blood and breath glucose levels in the porcine 
subjects. 
Standardization of EBC collection processes for individual biomarkers was 
recommended by the ATS/ERS task force in 2005 [48], and included in the findings are 
potential causes of variation when collecting breath samples. In order to troubleshoot the 
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4.2 Standardizing the Nebulizer Collection Procedure 
The ATS/ERS task force identified problems that translate to the nebulizer setup 
and include: assay accuracy, material interaction, and background interference. A 
diagram detailing these three identified problems is depicted in Figure 4.2.1. Because the 
accuracy and variability associated with each problem is dependent on the steps the come 
later in the process, it seemed prudent to investigate these issues beginning with assay 
accuracy working backward through the collection and measurement process. For all 
statistics shown, a generalized linear model with pairwise Tukey tests were run for 
analysis. 
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4.3 Assay accuracy 
The BioVision glucose assay kit is directly responsible for all the test results 
reported by this test. As such, it is imperative that the test is shown to be reliable for EBC 
samples and capable of providing consistent and accurate measurements.  
4.3.1 Protein concentration 
Differences between the compositions of the assay standard and EBC samples 
may affect accuracy. Most notably, the assay may require protein that is present in the 
provided standard but not collected during breath condensation [104].  
4.3.1.1 Methods 
The setup for the EBC collected to analyze protein concentration is depicted in 
Figure 4.3.1. For EBC samples from human subjects the user was asked to inhale through 
the nose and exhale normally into the mouthpiece for 5 minutes. The total protein 
concentration in the preliminary EBC samples, the glucose assay kit buffer, and the 
glucose assay kit standard at the highest (3.6 mg/L) concentration were determined using 
a BCA assay (Pierce Biotechnology Inc., Rockford IL) with a working range of 5-250 
µg/ml.  
 
Figure 4.3.1: Exhaled breath condensation and collection device.  The condensation tube 
runs through a container filled with dry ice, causing the breath and aerosol passing 
through the tube to condense. A section of the condensation tube is shown at a higher 
magnification to illustrate the condensation process. The user is shown breathing through 





To determine the most accurate assay parameters for quantifying glucose in 
aqueous samples (similar to EBC), we quantified the amount of protein in the standard 
glucose assay kit and compared that to the protein concentration in EBC and water 
samples.  Protein concentration in deionized water, EBC samples and components of the 
glucose assay kit are provided in Table 4.1. 
Table 4.1: Protein concentration in deionized water (n=3), EBC sample (n=3), the 
glucose assay kit glucose buffer solution (n=3), and the glucose assay kit glucose 
standard at concentrations of 3.6 mg/L (n=3) and 0.36 mg/L (n=3). Groups that do not 
share a letter are significantly different. 
 DI Water EBC Buffer 3.6 mg/L 0.36 mg/L 
Protein Concentration ( g/mL) 0.42 ± 1.11 6.26 ± 5.00 18.45 ± 0.73 26.13 ± 5.79 22.92 ± 5.25 
Groups B B A A A 
 
4.3.1.3 Discussion 
Since the protein content of the EBC sample is significantly less than the protein 
concentrations of the glucose assay kit standards, the provided standard may not provide 
an accurate representation of EBC glucose concentration. A standard more similar to 
EBC constitution, created of deionized water and commercial glucose, was created for 
use with EBC samples. 
 
4.3.2 Sensitivity 
To provide a more direct comparison with EBC samples using the glucose assay 
kit, a customized standard solution with no protein was created and compared to the 
original kit standard. 
4.3.2.1 Methods 
The custom standard was created using deionized water and D-(+)-Glucose 
(Sigma-Aldrich, St. Louis, MO) to obtain final concentrations of 0, 0.72, 1.44, 2.16, 2.88, 
and 3.6 mg/L, which are the same concentrations used in the glucose assay kit. Due to the 
low glucose concentrations of the samples being tested, the no-protein standard was also 
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run at even lower concentrations of 0.003, 0.0075, 0.015, 0.03, 0.06, 0.12, and 0.36 mg/L 
to extend the working range of the assay. The glucose assay kit was applied to both its 
provided standard and the custom standard to verify that the glucose assay kit could be 
used with EBC samples.  
4.3.2.2 Results 
Glucose measurements in standards created with the kit standard and the 
customized no-protein standard are shown in Figure 4.3.2. Both standards show low 
standard deviations, but the custom standard shows higher dynamic range of RFU values 
from the same glucose concentrations. Additionally, the no-protein standard remains 
linear at low glucose concentrations (Figure 4.3.3) below the stated accuracy range of the 
glucose kit.  For the remainder of the results in this study, we used the customized no-
protein standard since it was linear and had a large dynamic range. 
 
Figure 4.3.2: The standard curve generated by the kit standard (n=4) and the customized 
no-protein standard (n=3). Error bars represent the standard deviation of the samples. 
 
y = 394.04x + 86.976 
R² = 0.9832 
y = 1205.7x + 76.768 























As the no-protein glucose standard showed improved performance over the kit 
standard (Figure 4.3.2 and Figure 4.3.3) while maintaining a more physiologically 
relevant protein level, it was used for measurements of glucose concentrations. 
 
Figure 4.3.3: The standard curve generated by the customized no-protein standard (n=3) 
with an emphasis on the low glucose concentrations. Error bars represent the standard 
deviation of the samples. 
4.3.3 pH 
Previous work examining EBC acidification in acute lung injury found EBC pH 
to range between 5.5-6.5 [105]. As pH may influence the assay outcomes [106], a pH 
meter was used to measure pH before and after assaying samples. 
4.3.3.1 Methods 
The effect of EBC pH on glucose assay performance was evaluated using 
nebulized glucose solutions with pH in the range of prior work. Solution pH was 
measured using an electrode (MI-410, Microelectrodes, Inc., Bedford, NH) before 
(‘Initial Samples’) and after (‘With Reactive Mix’) the addition of the working reagents 
y = 1226.8x + 70.97 












Glucose Concentration (mg/L) 
No-protein Low Concentration 
33 
 
of the glucose assay. To evaluate interaction between glucose concentration and pH, 
collected glucose solutions within and above the range expected in EBC were tested (0, 
3.6, 7, and 36 mg/L). 
4.3.3.2 Results 
We measured the pH values before and after adding the glucose reaction mix to 
confirm that the glucose assay results will not be affected by the pH of the glucose 
samples.  The pH values of the different glucose solutions were not different from each 
other after assay buffer application (Fig. 4; ‘With Reactive Mix’). The samples, reported 
in Figure 4 along with pH values, are all buffered to approximately the same pH by the 
glucose reaction mix (‘With Reactive Mix’; p<0.001). 
 
Figure 4.3.4: pH measurements of different samples before (n=3) and after (n=3) the 




Varying pH levels can also lead to inconsistent measurements in some 
chemifluorescent assays [106]. Exploring this possibility, we found that a physiologically 































To ensure that the BioVision glucose assay kit does not react with other similar 
molecules, the other simple monosaccharaides were tested with the kit. 
4.3.4.1 Methods 
To confirm assay specificity for glucose, standards of deionized water and both 
D-(-)-Fructose (Avantor, Center Valley, PA) and D-(+)-Galactose (Sigma-Aldrich, St. 
Louis, MO) were made with concentrations of  0, 0.72, 1.44, 2.16, 2.88, and 3.6 mg/L 
and compared. 
4.3.4.2 Results 
To ensure that the glucose assay kit is quantifying the concentration of glucose 
and not some other monosaccharides, we test the assay output for fructose and galactose.  
The glucose kit showed no cross-reaction with other monosaccharides, such as fructose 
or galactose, suggesting that the assay is highly specific for glucose as reported by the 




Figure 4.3.5: Equivalent concentrations of glucose, galactose, and fructose in solution as 
assayed by the glucose assay kit. (n=3) 
4.3.4.3 Discussion 
The kit is specific for glucose and does not cross react with other 
monosaccharides.  
4.3.5 Conclusion 
With the simple standard of deionized water and glucose replacing the kit 
standard, the BioVision Glucose Assay Kit could act as a viable EBC glucose 
quantification assay. Confidence in the assay kit readings lends to analyzing the next step 
in the nebulizer set up diagram, material interaction. 
 
4.4 Material Interaction 
The ATS/ERS task force notes that each desired biomarker should be individually 
analyzed for ideal collection materials [48]. Potential materials to be evaluated were 
selected from commercialized EBC collection devices and materials appearing in current 
EBC research [55].  
y = 2174.2x + 262.04 























Condensation tubes of Teflon, stainless steel, and glass were used with outer 
diameters of 9/32” (with the exception of Teflon with an OD of 1/4") and wall thickness 
ranging from 0.0625”-0.14”. A pipette was used to insert one milliliter of glucose 
solution of various concentration (0, 1.8 or 3.6 mg/l) into a tube of each material. The 
tubes were rolled for five minutes before pouring the sample into a microcentrifuge tube 
and assaying the sample with the glucose assay kit.  
To assess the material effects on glucose measurement as the samples change 
physical states, a second test was run to assess material interactions as glucose solutions 
were frozen and thawed within the tubes. In this test, 1 ml of the glucose solution was 
placed in the tube with a pipette, and the entire tube was placed in a container filled with 
dry ice, as depicted in Figure 4.1.1, for 5 minutes. The tube was then thawed and the 
resulting solution was removed and assayed for glucose.  
4.4.2 Results 
Interaction effects for the four potential collection materials tested are provided in 
Figure 4.4.1. While all of the materials with the exception of glass have no statistical 
effect on the glucose measurement, Teflon showed the highest correlation with glucose 
concentration in the original solution. Also noteworthy is how much variance a glass 
collection system introduces to the samples. As this variability is undesired in the system, 
the glass collection device was left out of the freeze/thaw experiment. 
The effect of freezing and thawing on the glucose solution measurements are 





Figure 4.4.1: Results of material contact interaction test for Stainless Steel (n=6), Teflon 
(n=6), Polyethylene (n=6), and Glass (n=6). Stock solution (n=6) is shown for 
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Figure 4.4.2: Results of material freeze/thaw test for Stainless Steel (n=3), Teflon (n=3), 
Polyethylene (n=3), and Stock solution (n=3) is shown for comparison. Groups that do 
not share a letter are significantly different. 
 
4.4.3 Discussion 
Teflon performed the most consistently of all the materials and provided no 
distinguishable change in solution concentration as can be seen in Figure 4.4.1 and Figure 
4.4.2. Its reliability and inert nature toward glucose suggest that Teflon is an appropriate 
material for glucose collection. As both stainless steel and polyethylene also showed no 
statistical alteration in glucose concentration, either material could be potential EBC 
glucose collection device materials allowing some adaptability to any glucose 
measurement setup. However, as directed by the ARS/ETS task force, consistency 
amongst experiments is the goal of this study and as such Teflon is recommended for the 
quantification of glucose in EBC. The erratic nature of the glass tube measurements may 
be explained by the glucose in the tube gaining charge and preferentially adhering to the 

























































Teflon will be used for glucose EBC collection purposes as it had no statistical 
effect on glucose solutions and had the highest correlation coefficient with the stock 
solution. With an identified condensation material, it is possible to assess the final portion 
of the collection diagram, the background interference. 
4.5 Background Interference 
Exhaled breath is largely comprised of inhaled air [56], which may contain 
interfering compounds. The composition of exhaled air has been shown to have some 
dependence on the composition of the air inhaled [108]. In order to accurately measure 
components of EBC, the starting composition of the air must be determined.  
 
4.5.1 Ambient measurements 
Before background interference can be corrected for, it must be detected and 
measured. 
4.5.1.1 Methods 
Background air collection was performed using a setup similar to that seen in 
Figure 1b without a nebulizer. Total collection time was 5 minutes. The Teflon tube was 
then removed from the dry ice and thawed to room temperature, and the resulting 
solution was poured into a microcentrifuge tube and assayed for glucose. To examine 
different background air samples, this same test was performed in the laboratory, in a 
nearby park, and using dry, cleaned air (oil-free, 0.2 µm filtered pressurized air with a 
dew point of -40 °C). As the dry, cleaned air does not contain enough moisture to 





The glucose concentration reported from condensed samples from laboratory air, 
outside air, dry and clean air (bubbled through deionized water), and water nebulized in 
the laboratory were compared to deionized water in Figure 4.5.1. Air collected from 
outside contained a higher glucose concentration than all the other samples (p<0.001), 
while laboratory air and the condensate collected from the nebulizer run with deionized 
water output were statistically not different and significantly higher than the water, 
remnants of the nebulizer and clean air collections (p<0.001). 
 
Figure 4.5.1: Glucose concentration from stock deionized water (n=18), dry and cleaned 
air bubbled through deionized water (n=3), nebulizer remnants of deionized water 
(n=18), condensate collected from the nebulizer run with deionized water (n=18), 
condensed lab air (n=12), and condensed outside air (n=3). Groups that do not share a 
letter are significantly different. 
 
4.5.1.3 Discussion 
As can be seen in Figure 4.5.1, condensed ambient air contains detectable 
atmospheric glucose contamination that would affect EBC measurements. Additionally, 
the amount of interferent present appears to depend on location. We hypothesize that 
differences in laboratory and park flora, fauna, and potential industrial sources (e.g. Tate 
& Lyle) may contribute to the stark differences seen in the condensation collections. 








































Collections from aerosolized deionized water, the corollary to EBC with no glucose, 
yielded concentrations indistinguishable from condensing background air. It is therefore 
imperative that a measurement of the environmental glucose be taken prior to any breath 
analysis.  
 
4.5.2 Nebulizer mixture model 
Nebulized glucose collection may be modeled as the result of a mixture of 
atmospheric interferent and input glucose solution. The contributions from the input 
glucose and the atmospheric interferent are dependent upon the fraction of the air sample 
that can be condensed in our device: this is directly related to the humidity of the air 
samples. In this case it is possible to relate collected glucose measurements to the input 
glucose solution concentration by measuring the humidity of the atmosphere and the air 
to be condensed. The relation between the glucose concentrations and humidity is defined 
below: 
[          ]  [     ]                [          ]                     
Equation 4.1: Nebulizer mixture model 
 
where brackets represent glucose or atmospheric interferent concentrations. The fractions 
of condensed sample may be estimated with humidity: 
                    
                  
                           
 
                                    
4.5.2.1 Methods 
A repeat of the experiment detailed in section 4.1.2 was performed with the 
addition of ambient humidity measurements. Humidity measurements were performed 
with a VWR humidity sensor (VWR, Arlington Heights, IL). The stock glucose 
concentration, ambient glucose concentration, and ambient humidity are used in 





Since the relationship between the measured glucose concentrations of the 
condensed samples differed from the stock solution concentrations that were nebulized, 
we applied the mixture model to correct for the effects of the background interference.  
Using the mixture model in Equation 4.1, we show that it is possible to estimate the 
glucose concentrations of the collections from the stock solutions in Figure 4.5.2. The 
generalized linear model found no significant difference between the model estimation 
and measured output. 
 
Figure 4.5.2: Mixture model estimated glucose concentration of the condensate 
concentration from the known stock sample compared to the measured collection glucose 
concentrations. Groups that do not share a letter are significantly different. 
 
4.5.2.3 Discussion 
Attempting to account for the mixture of the background air with the sample air, 
the concentration of the glucose in the condensate is estimated from the known stock 
solutions by the nebulizer mixture model (Figure 4.5.2). The nebulizer mixture model can 



































Glucose Concentrate of Input (mg/L) 
Collected and Predicted Condensate 
Concentrations 
Measured Condensate Concentration
Nebulizer Mixture Model Prediction
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the result of a mixture of atmospheric interferent and ELF glucose we can relate EBC 
glucose measurements to ELF concentrations once again by measuring the humidity of 
the atmosphere and the condensed air collected. The glucose concentration of the EBC as 
parallel to the nebulizer model: 
[   ]  [   ]              [          ]                     
Resulting from this model the glucose concentration in the ELF can be estimated: 
[   ]  
[   ]  [          ]                    
           
 
A relationship as demonstrated above may provide insight connecting EBC 
samples to blood glucose levels; as such, humidity measurements and ambient glucose 
measurements are recommended to complement glucose EBC work. These measurements 
elucidate the environmental contribution to an EBC measurement, minimizing the 
uncertainty of changing environments and the variables therein. 
 
4.5.3 Conclusion 
Following the indications from these findings yields a viable EBC collection 
protocol. With the ability to confidently monitor the glucose concentration in exhaled 
breath, glucose can be more readily used as a biomarker in EBC. In particular, blood 
glucose may then be inferable from the EBC measurements, as ELF comes to equilibrium 
with the blood in the capillaries surrounding the alveoli [53]. Although no simple 
equilibrium explains how all of the concentrations of molecules in ELF relate to blood, 
some such relationships have been explored [109]. If there exists such a relationship for 
glucose between ELF and blood, breath glucose may be used to monitor metabolism non-





4.6 Standardized Collection and Measurement of Glucose in Aerosol 
An accurate and reliable measurement technique for glucose from aerosol is 
detailed in this study. The procedure includes a customized standard using the BioVision 
Glucose Assay Kit to quantify the glucose, Teflon to collect the sample, and a nebulized 
glucose standard curve to relate the collection results to the glucose concentration in the 
aerosol. It has been found that a glucose signal is measured in the ambient air, and this 
contributes to a variation in the glucose level in nebulized glucose solutions, especially 
when the glucose concentration is low.  Thus, it is critically important to compensate for 
the background glucose signal originating from ambient air in accurate estimation of the 
glucose present in EBC. The tested protocol for aerosolized glucose collection provided 
insight that should enable the reliable measurement and should prove to be a reliable 
method to quantify glucose in exhaled breath condensates. Future research will apply 
these techniques to investigate the relationship between glucose concentrations exhaled in 






5 HUMAN SUBJECT STUDY 
The IRB approved study number 1205012274 R002, entitled ‘Glucose Detection 
on Exhaled Breath Samples’, set out to utilize the standardization achieved in the 
previous chapter to establish a functional relationship between blood and breath glucose 




5.1.1 EBC collection procedure 
The EBC collection device is based on the findings of previous chapter and is 
depicted in Figure 5.1.1. The breath collection setup device is similar to that of the 
porcine study seen in Figure 3.1.1, with a few major differences. The human setup has no 
solenoid valve, one-way valve, nor collection reservoir and instead has a Teflon 
condensation tube. Removing the solenoid valve removed a significant amount of non-
functional device space; however, it was still necessary find another way to remove the 
lung dead space. The dead space in human adults ranges from 150-200 mL [110]. To 
remove this from the collection, the subjects were asked to inflate a 200 mL balloon prior 
to breathing into the collection device. The one-way valve and collection reservoir were 
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removed based on the findings of the ARS/ETS task force, which suggest that a majority 
of EBC research is being performed with direct collection as seen in Figure 5.1.1 [48]. 
 
Figure 5.1.1: Human breath collection setup 
 
The subject wore a nose-clip during collection. A typical breath cycle for a patient 
during EBC collection is as follows: inhale through mouth, exhale into 200 mL balloon, 
and then exhale into device. When breathing into the collection setup, the subject’s 
mouth was in contact with an individual mouthpiece containing a saliva trap. The breath 
is then passed through a capnometer, pneumotachometer, and temperature sensor (not 
shown in Figure 5.1.1) before condensing in the condensation tube. Each EBC sample 
consisted of 50 L of condensed breath as measured by the pneumotachometer, taking 
~10-15 minutes per sample and providing enough condensate for three assay readings. 
Additionally, ambient humidity and background glucose measurements, as described in 
Chapter 4: COLLECTION AND MEASUREMENT OF GLUCOSE IN AEROSOL and 
seen in Figure 5.1.2, were collected simultaneously with EBC collection. Once the patient 
exhaled 50 L, the condensation tube was removed and allowed to thaw to room 
temperature. The tube contents were poured into a 2 mL microcentrifuge and stored at -
80°C.  
All samples were analyzed using the BioVision glucose assay kit with a deionized 
water and glucose standard within five days (#K606-100, http://www.biovision.com). At 




Figure 5.1.2: Background air collection setup 
 
5.1.2 Correction for background 
The nebulizer mixture model was adjusted for anticipated use with EBC 
collections. Assuming that EBC collections are the result of a mixture of atmospheric 
interferent and ELF glucose we can relate EBC glucose measurements to ELF 
concentrations once again by measuring the humidity of the atmosphere and the 
condensed air collected. The glucose concentration of the EBC as parallel to the nebulizer 
model: 
[   ]  [   ]              [          ]                     
Resulting from this model the glucose concentration in the ELF can be estimated: 
[   ]  
[   ]  [          ]                    
           
 
 
The exhaled breath is assumed to be at 100% relative humidity, as in the case of 
the nebulizer [110]. Therefore, similar humidity fractions were used in EBC case as the 
original nebulizer mixture model. This model was used to estimate the glucose 
concentration in the ELF to provide ELF glucose data to compare to blood glucose levels. 
5.1.3 IRB Procedure 
‘Glucose Detection on Exhaled Breath Samples’ included the approval of two 
separate studies, Study A and Study B. A subject participating in one study was not 




5.1.3.1 Study A 
For this study, subjects were asked to fast for four hours prior to the study. Three 
EBC collections, preceded and succeeded by blood glucose level measurements, were 
taken in succession prior to the provision of a meal. Upon collection of these initial three 
EBC collections, subjects were provided a meal in order to increase their blood glucose 
level. Immediately following the meal, six EBC samples along with their corresponding 
blood glucose level measurements were taken in succession. Each EBC sample was 
considered complete when the subject had exhaled a total of 50 L of air, taking ~10-15 
minutes. Before and after each EBC collection a droplet of blood was acquired from the 
subject’s fingertip using a lancet and applied to an ACCU-CHECK Nano glucometer 
(Roche Diagnostics) to quantify subject blood glucose level. The overall procedure took 
place over the course of ~2.5-3 hours. 
5.1.3.2 Study B 
For this study, subjects were asked to fast for four hours prior to the study. Three 
EBC collections, preceded and succeeded by blood glucose level measurements, were 
taken in succession prior to the provision of a glass of water. Upon collection of these 
initial three EBC collections, subjects were provided a glass of water to serve as a control 
to Study A. Immediately following the water consumption, three EBC samples along 
with its corresponding blood glucose level measurements were taken in succession. Each 
EBC sample was considered complete when the subject had exhaled a total of 50 L of air, 
taking ~10-15 minutes. Before and after each EBC collection a droplet of blood was 
acquired from the subject’s fingertip using a lancet and applied to an ACCU-CHECK 
Nano glucometer (Roche Diagnostics) to quantify subject blood glucose level. The 
overall procedure took place over the course of ~1.5-2 hours. 
It should be noted that the final three EBC collections of Study B can be used as 
the first three EBC samples of Study A. Refer to Appendix B 




5.1.3.3 Subject demographics 
A total of 3 normal healthy human subjects, all male ages 20-23, volunteered to 
participate in both studies.  
 
5.2 Results 
The raw EBC and blood glucose level collections of a representative human 
subject are shown in Figure 5.2.1. This data is a bit erratic and the EBC glucose values 
have no apparent relationship to the blood glucose values. Additionally, the EBC values 




Figure 5.2.1: Whole blood (red) and EBC (blue) glucose level trend of a human subject. 
Provided water is indicated by the dashed gray line and provided meal is indicated by the 
































































Figure 5.2.2 shows the EBC glucose values next to their corresponding 
background values and the glucose concentration the background is predicted to 
contribute the EBC concentration. Both the background and the predicted background 
contribution to EBC concentration are higher than the measured EBC glucose 
concentration (p < 0.001; n=3). Refer to Appendix C 
Whole Human Study Data for the remainder of the human data. 
 
Figure 5.2.2: Comparing EBC glucose levels to background glucose levels 
 
5.3 Discussion 
The erratic EBC glucose values seen in Figure 5.2.1 were expected, as this is data 
before applying the nebulizer mixture theory. However, the expectation was that using 
the nebulizer mixture model to predict ELF concentration from EBC concentrations 
would allow a more straight-forward relationship between ELF and blood glucose 
concentrations. This is not the case, as seen in Figure 5.2.2. The measured EBC 






































but less than that interference is supposed to contribute to the EBC concentration. The 
human subject inhaled a higher glucose concentration than was exhaled. This suggests 






6 CONCLUSIONS AND FUTURE WORK 
6.1 Conclusions 
In Section 1.5 the goals for this master’s thesis were listed. Each goal and a 
summary of the conclusions from each goal follow. 
 
 Standardize a method of collecting and measuring glucose concentrations 
from aerosol 
 
This was initially intended to be accomplished through the PACUC 
approved porcine study. However, as that study was deemed too unethical 
to continue based on the procured results, another method of standardizing 
the collection process was developed. Using a nebulizer to remove the 
biological uncertainty, it was determined that utilizing the BioVision 
glucose assay kit to measure glucose concentration, a Teflon condensation 
tube surrounded by dry ice for collection, and the nebulizer mixture model 
to account for background interference allows for accurate measurement 





 Design a device to collect exhaled breath condensate 
 
A device that measures CO2 content, air flow, temperature, and humidity 
was created while accounting for the standardization achieved in the first 
goal. The device has the subject breathe through a mouthpiece, 
capnometer, pneumotachometer, temperature sensor, and then the Teflon 
collection tube. Meanwhile, ambient humidity and background glucose 
concentration is recorded throughout the breath collection. Once the EBC 
is collected, the BioVision glucose assay kit is used to analyze the data. 
 
 Evaluate the relationship between exhaled breath condensate glucose 
levels and blood glucose levels 
 
An IRB approved study was employed to quantitatively evaluate the 
change in both blood and EBC glucose. The human subject study results 
indicate that humans are exhaling less aerosolized glucose than they are 
inhaling.  
 
6.2 Future Work 
6.2.1 Investigate origin of glucose presence in ambient air 
This study would measure background glucose interference levels from many 
locations. It would be ideal to have measurements from high fauna population areas, high 
flora population areas, and different industrial sites. Comparing the glucose levels of 
these different background environments should allow for the identification of factors 
that contribute to glucose interference in background air. Additionally, it may be useful to 




6.2.2 Explore methods of glucose retention in respiratory system 
Subjects could be asked to inhale different background air glucose concentrations 
for a regulated period of time, allowing the respiratory system to acclimate to the new 
background. Then EBC and background glucose measurements can be collected and 
compared to confirm that the subject removes glucose from the air inhaled. The different 
backgrounds will allow for a relationship between background glucose level and airway 
glucose retention to be identified; the clean air background would provide a control 
allowing for analysis of EBC glucose produces solely by the respiratory system. 
Additionally, taking EBC measurements of the dead space and deep lung air separately 
may indicate where in the airway glucose retention may be occurring. 
6.2.3 Revisit breath-to-blood glucose level functional relationship 
6.2.3.1 Multi-day fasting EBC study 
This study would measure blood and EBC glucose levels while fasting several 
times a day for five days. Having fasting blood and EBC glucose levels over the course 
of the day and over the course of the week provides a thorough sample of fasting glucose 
levels. These data would provide means to properly assess the variability of the blood and 
EBC glucose level relationship while fasting. 
6.2.3.2 EBC glucose study with extreme blood glucose levels 
The human subject study run for this work analyzed the blood-EBC glucose level 
relationship through a normal range of blood glucose values. The proposed study would 
collect EBC samples from both hyperglycemic and hypoglycemic subjects. The abnormal 
blood glucose states could be induced with liquid dextrose and insulin and the study may 
have to be done in an animal model for ethical reasons. The data this study would collect 
would provide a more accurate understanding of the working range of the blood-EBC 





6.2.3.3 Variable exhalation method study 
Each subject participating in this study would be provided very detailed 
instructions of how to exhale while EBC collection is occurring. Referring to Table 3.1 
provides a range of breathing styles that could be tested in this manner. However, with 
human subjects, the test would not be limited to how breath can be controlled via phrenic 
nerve stimulation and chest compression. Human subjects can be told to inhale until their 
lungs cannot take in anymore air and they could be asked to exhale their full lung 
volume. Additionally, given a metronome, humans will be able to breath in very 
controllable rhythms. This data would provide more information on the blood-EBC 
glucose level relationship, specifically if the relationship is breath style dependent. It may 
also give some insight to the mechanism of small, non-volatile particle aerosolization in 
the breath. 
 
6.2.3.4 Subject diversity study 
All the subjects that participated in the human subject study for this work were 
college age non-diabetic adults. Given that EBC glucose monitoring is a design to aid in 
the life of diabetic patients, it seems logical to confirm this relationship in diabetic 
subjects. While expanding the subject list, adding age groups and subjects with diabetes 
related complications will more appropriately represent the patient base this technology is 
geared toward. 
6.2.3.5 Other directions 
Once the studies proposed above have established the capabilities of an EBC 
based blood glucose monitoring system, the next steps would be to apply the findings of 
this work to a handheld device. The proposed devices thus far, for example, do not 
account for a background and do not contain humidity measurements. These will need to 
be added to any design in addition to the findings of future studies.  
Furthermore, the method of EBC collection and measurement used in these 
protocols require at least ten minutes of collection time. For hand-held device purposes, a 
small sensor would likely serve better than an assay requiring a spectrophotometer. 
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Changing measurement methods may allow for a more convenient sampling time and 
simpler miniaturization of the device. 
 
All future directions should continue toward getting a non-invasive blood glucose 
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Whole Pig Study Data 
 
Figure A.1: Blood and breath data from Pig 1 
 
 













































































































































Figure A.3: Blood and breath data from Pig 3 
 
 








































































































































Figure A.5: Blood and breath data from Pig 5 
 
 








































































































































































































































Whole Human Study Data 
 
Figure C.1: Blood and breath data from Human 1 
 
 


































































































Figure C.3: Blood and breath data from Human 2 
 
 




































































































Figure C.5: Blood and breath data from Human 3 
 
 


























































































Human 3: EBC and Background 
Background
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